RLFTF (Relief Therapeutics Holding) EBIT : $-59.08 Mil (TTM As of Jun. 2024)

View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding EBIT?

Relief Therapeutics Holding's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2024 was $-4.27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2024 was $-59.08 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Relief Therapeutics Holding's annualized ROC % for the quarter that ended in Jun. 2024 was -15.52%. Relief Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -264.93%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Relief Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2024 was -135.59%.

Relief Therapeutics Holding EBIT Historical Data

The historical data trend for Relief Therapeutics Holding's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding EBIT Chart

Relief Therapeutics Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-12.24

-6.94

-37.71

-56.77

-128.76

Relief Therapeutics Holding Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EBIT	Get a 7-Day Free Trial															-28.17	-27.43	-71.03	-54.81	-4.27

Competitive Comparison of Relief Therapeutics Holding's EBIT

For the Biotechnology subindustry, Relief Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relief Therapeutics Holding's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's EV-to-EBIT falls into.

Relief Therapeutics Holding EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-59.08 Mil.

Relief Therapeutics Holding (OTCPK:RLFTF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Relief Therapeutics Holding's annualized ROC % for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-9.064 * ( 1 - -14.02% )	/	( (69.125	+	64.039)	/ 2 )
=	-10.3347728	/	66.582
=	-15.52 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	88.333	-	6.031	-	( 16.832	-	max(0, 7.989	-	21.166	+	16.832	))
=	69.125

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	79.348	-	4.179	-	( 12.003	-	max(0, 5.329	-	16.459	+	12.003	))
=	64.039

Note: The Operating Income data used here is two times the semi-annual (Jun. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Relief Therapeutics Holding's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Jun. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-8.548	/	( ( (3.431 + max(-4.586, 0))	+	(3.022 + max(-2.596, 0)) )	/	2 )
=	-8.548	/	( ( 3.431	+	3.022 )	/	2 )
=	-8.548	/	3.2265
=	-264.93 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.354	+	0.644	+	0.409)	-	(6.031	+	0.132	+	0.83)
=	-4.586

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1.079	+	0.418	+	0.791)	-	(4.179	+	0.477	+	0.228)
=	-2.596

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Relief Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2024 )
	=	-59.08	/	43.574
	=	-135.59 %

Relief Therapeutics Holding EBIT Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Relief Therapeutics Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

RLFTY:USA RLFz:UK 0QKQ:UK RLF:Switzerland

Address

Avenue de Secheron 15, Geneva, CHE, 1202

Website

https://www.relieftherapeutics.com

Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development such as RLF-TD011, and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast among others. Geographically the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.